Product Description
SOR-C13, is a novel, short, synthetic peptide developed from the C-terminal region of Soricidin, our proprietary 54 amino acid peptide. SOR-C13 binds with affinity and selectivity to - and disrupts the function of - TRPV6, a calcium channel over-expressed in solid tumor cancers.Ê (Sourced from: https://www.soricimed.com/sor-c13.htm)
Mechanisms of Action: TRPV6 Inhibitor
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Soricimed Biopharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Prostate Cancer|Ovarian Cancer|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2018-02835 | P1 |
Completed |
Pancreatic Cancer|Ovarian Cancer|Prostate Cancer |
2023-06-20 |
|
| SOR-C13 01 | P1 |
Completed |
Ovarian Cancer |
2015-07-01 |